What this trial studies
The goal of this clinical pilot trial is to learn about the feasibility of a high-intensity resistance training intervention in peri- and early menopausal females. The main question it aims to answer are: -Is a 9-month resistance training intervention feasible (e.g., recruitment rates, protocol adherence, attrition) Secondary aims include examining changes in bone health, muscle strength, and menopausal symptoms. Participants will participate in a 9-month progressive, supervised, resistance training intervention. Researchers will compare secondary outcomes between the exercise group and a wait-list control group.
Conditions in scope
- Bone Loss
- Bone Loss, Age-related
- Osteoporosis
- Musculoskeletal Diseases
Interventions
- Resistance Training (Other) — Twice weekly resistance training progressing to 5 sets of 5 repetitions of 80-90% of one repetition maximum.
Who can join
Women only · Ages 45 Years to 60 Years · Accepts healthy volunteers.
Inclusion criteria
- years old.
- Menopause status of peri- or early menopausal: stages -2 or -1 of the stages for reproductive aging 10+ staging system or are within 5 years of their last known menses.
Exclusion criteria
- Females who are pregnant or planning pregnancy within the next year.
- Orthopaedic conditions that may be made worse with exercise.
- Has low back pain, hypertension, lipidemia, diabetes, or cardiovascular disease.
- Has a history of metabolic bone disease.
- Has had an osteoporotic fracture within the last 5 years.
- Had previous treatment with osteoporosis pharmacotherapy.
- Has active glucocorticoid use.
- Is currently participating in progressive resistance training or has in the previous 6 months.
Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.
Where it’s happening
| City | State / Region | Facility | Site status |
|---|---|---|---|
| Calgary | Alberta | University of Calgary | Unknown |
Status & timeline
- Overall status: Active, not recruiting
- Study type: Interventional
- Phase: N/A
- Start date: 2023-11-01
- Primary completion: 2025-02
- Last update posted: 2024-12-05
- First posted: 2023-07-27
Sponsor & contact
Lead sponsor: University of Calgary (Other)
For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.
Outcome measures
Primary outcomes
- Feasibility - Recruitment (Over 9 months)
Recruitment rates - number of participants recruited per month and number of eligible participants who consented. - Feasibility - Adherence (Over 9 months)
Protocol adherence (number of exercise sessions participants attend) will be expressed as a percent. - Feasibility - Attrition (Over 9 months)
Attrition (number of randomized participants with valid outcome data) will be expressed as a percent.
Related ClearedRx care
If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.
Important. Information from ClinicalTrials.gov as of May 8, 2026. Trial details (status, sites, contacts, eligibility, outcomes) change frequently — always check the official record at https://clinicaltrials.gov/study/NCT05961371 before contacting a site.
ClearedRx is not affiliated with this trial or its sponsor. We index public-domain ClinicalTrials.gov records to help patients find evidence-based context for menopause care decisions. ClearedRx itself is a telehealth menopause/HRT brand — we do not enroll patients in trials.